# EDGAR Filing Document

**Accession Number:** 0001900304
**File Stem:** 0001654954-26-000179
**Filing Date:** 2026-1
**Character Count:** 6602
**Document Hash:** 111e920a4abdf8abcc1b7cb69ee42e19
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001654954-26-000179.hdr.sgml**: 20260108

**ACCESSION NUMBER**: 0001654954-26-000179

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260108

**FILED AS OF DATE**: 20260108

**DATE AS OF CHANGE**: 20260108

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Haleon plc
- **CENTRAL INDEX KEY:** 0001900304
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41411
- **FILM NUMBER:** 26517866

**BUSINESS ADDRESS:**
- **STREET 1:** BUILDING 5, FIRST FLOOR
- **STREET 2:** THE HEIGHTS
- **CITY:** WEYBRIDGE
- **STATE:** X0
- **ZIP:** KT13 0NY
- **BUSINESS PHONE:** 44 1932 822000

**MAIL ADDRESS:**
- **STREET 1:** BUILDING 5, FIRST FLOOR
- **STREET 2:** THE HEIGHTS
- **CITY:** WEYBRIDGE
- **STATE:** X0
- **ZIP:** KT13 0NY

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DRVW 2022 Ltd
- **DATE OF NAME CHANGE:** 20211217

**UNITED STATES**

 **SECURITIES AND EXCHANGE COMMISSION**

 **Washington, D.C. 20549**

 **FORM 6-K**

 **REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

 **For the month of January 2026**

 **Commission File Number: 001-41411**

 **Haleon plc**

(Translation of registrant's name into English)

 **Building 5, First Floor, The Heights,**

 **Weybridge, Surrey, KT13 0NY**

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

 **EXHIBIT INDEX**

---

| | |
|:---|:---|
| <u>Exhibit Number</u> | **Description** |
| 99.1 | 08 January 2026 - "Evolution of operating model" |

---

99.1 ![](a2009o000.jpg)

 **Haleon announces evolution of its operating model to drive growth and agility**

 **08 January 2026:** Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) has today announced that it is evolving its operating model in support of its Win as One strategy to drive its growth, productivity and culture agenda, as set out at its Capital Markets Day in May 2025. These changes are expected to be implemented by mid-2026.

***<u>Chief Growth Officer</u>***

Haleon has today created a new Chief Growth Officer (CGO) role. This role will include broad responsibility across Haleon's existing Category, Marketing and Strategy functions, as well as a new global Commercial Excellence team. The CGO will lead Haleon's growth and innovation agenda in partnership with Haleon's new Operating Units (as below) and the existing R&D and Supply Chain functions, to better leverage Haleon's global footprint and capitalise on the strength and breadth of its brand portfolio, in support of the ambitions set out in May 2025.

***<u>Operating Units</u>***

Haleon is creating six Operating Units (OUs) to enable the Company to capitalise on the significant growth opportunities in its key markets, with each OU responsible for delivering business performance through the execution of Haleon's category strategies.

The current EMEA & LatAm region will be separated into three constituent OUs: **Latin America** (LatAm), **Middle East and Africa** (MEA) and **Europe**. Recognising the strength of Haleon's business in **India Subcontinent** (ISC) and the opportunities for growth, ISC will become its own OU, separate from **Asia Pacific**. Haleon's **North America** OU remains unchanged.

***<u>Global Functions</u>***

Haleon's global functions remain responsible for setting functional priorities in support of delivering its Win as One strategy and for driving a consistent approach globally, making the right strategic choices to benefit the end-to-end organisation. Haleon has appointed a new Chief Transformation Officer (CTO), who will be responsible for coordinating and driving the significant transformation across Haleon's business processes, operating model, and technology changes.

The CGO and CTO, along with the President of each OU, will be part of Haleon's Executive Committee and will report directly to Chief Executive Officer, Brian McNamara. Biographies for Haleon's full Executive Team, including all newly appointed members, can be found at <u>www.haleon.com/who-we-are/leadership</u>.

 **Brian McNamara, Chief Executive Officer of Haleon commented:** "In May 2025, we introduced our Win as One strategy, which is how we will unlock Haleon's full potential, as we transform into a world-class consumer company. The changes we're making to our operating model are an important part of us delivering against our strategy to drive growth and will result in a simpler and more agile and efficient organisation."

Haleon will share more detail as part of its Preliminary Full Year Results scheduled for 25 February 2026 and will consult with employee representatives as appropriate.

 **Enquiries**

---

| | | | |
|:---|:---|:---|:---|
| **Investors** | **Investors** | **Media** | **Media** |
| Jo Russell | +44 7787 392441 | Zoë Bird | +44 7736 746167 |
| Rakesh Patel  | +44 7552 484646 | Victoria Durman | +44 7894 505730 |
| <br> Email: investor-relations@haleon.com | <br> Email: investor-relations@haleon.com | <br> Email: corporate.media@haleon.com | <br> Email: corporate.media@haleon.com |

---

 **About Haleon**

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as *Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu* and *Voltaren* - are built on trusted science, innovation and deep human understanding.

For more information, please visit <u>www.haleon.com</u>.

 **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  | **HALEON PLC**<br> *(Registrant)* | **HALEON PLC**<br> *(Registrant)* |
| Date: January 08, 2026 | By: | /s/ Amanda Mellor | /s/ Amanda Mellor |
|  |  | Name: | Amanda Mellor |
|  |  | Title: | Company Secretary |

---

<br>